Medpace Hldgs Q2 2024 GAAP EPS $2.75 Beats $2.54 Estimate, Sales $528.104M Miss $528.440M Estimate
Portfolio Pulse from Benzinga Newsdesk
Medpace Holdings (NASDAQ: MEDP) reported Q2 2024 GAAP EPS of $2.75, beating the analyst estimate of $2.54 by 8.27%. However, sales of $528.104 million slightly missed the estimate of $528.440 million. EPS increased by 42.49% YoY, and sales grew by 14.59% YoY.
July 22, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Medpace Holdings reported strong Q2 2024 earnings with GAAP EPS of $2.75, beating estimates by 8.27%. However, sales of $528.104 million slightly missed expectations. EPS increased by 42.49% YoY, and sales grew by 14.59% YoY.
The strong EPS performance, beating estimates by 8.27%, is likely to positively impact the stock price in the short term. The slight miss in sales is not significant enough to offset the positive sentiment from the EPS beat and YoY growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100